Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cadila Of India, WHO To Collaborate On Rabies Treatment

This article was originally published in PharmAsia News

Executive Summary

India's Cadila Healthcare said its Zydus Cadila arm and the World Health Organization have agreed to collaborate on a possible treatment for rabies. In a stock exchange filing, Cadila said the aim of the agreement is to develop a drug cocktail based on monoclonal antibodies to treat the disease that results from a bite by a rabid animal. WHO is to provide antibodies with the potential of neutralizing the rabies virus, along with the genetic sequences of the virus. Cadila's Zydus Research Center is to evaluate the possibility of that information leading to an adjuvant therapy. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts